Trial Profile
A Phase IIb Trial of Vorinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma Patients Refractory to Previous Lenalidomide Containing Regimens
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms RZD
- 21 Dec 2021 Status changed from active, no longer recruiting to completed.
- 21 Aug 2015 Planned End Date changed from 1 May 2015 to 1 May 2016 according to the ClinicalTrials.gov record.
- 21 Aug 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 according to the ClinicalTrials.gov record.